# BI-1910

Source: https://onco.cc/drugs/bi-1910/  
OnCo record `bi-1910` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BI-1910 is an experimental monoclonal antibody from BioInvent International, in phase 2 trials for advanced solid tumours, non-small-cell lung cancer and hepatocellular carcinoma.

## Summary

BI-1910 is a monoclonal antibody (agonist) from BioInvent International, with Merck & Co. as partner. An agonist anti-TNFR2 antibody, described by BioInvent as a differentiated agonist approach compared with its antagonist anti-TNFR2 antibody BI-1808; tested alone and with pembrolizumab in solid tumours. Its furthest stage is phase 2, for advanced solid tumours, non-small-cell lung cancer and hepatocellular carcinoma. ClinicalTrials.gov registers it in one study linked below. Phase 1/2a NCT06205706 active, not recruiting (registry, checked 3 Nov 2026). Company page says phase 2a single-agent work was planned for H1 2025 including HCC. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: BI-1910
- Modality: Monoclonal antibody (agonist)
- Mechanism: An agonist anti-TNFR2 antibody, described by BioInvent as a differentiated agonist approach compared with its antagonist anti-TNFR2 antibody BI-1808; tested alone and with pembrolizumab in solid tumours.

## Sources

- BioInvent International: bioinvent.com: https://www.bioinvent.com/en/clinical-programs/our-programs/bi-1910
- BioInvent International: bioinvent.com: https://www.bioinvent.com/en/clinical-programs/our-programs/bi-1910
- ClinicalTrials.gov: trials of BI-1910: https://clinicaltrials.gov/search?intr=BI-1910

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [BioInvent International](https://onco.cc/companies/bioinvent-international/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)
- trials: [BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors](https://onco.cc/trials/nct06205706/)

---
JSON: https://onco.cc/api/v1/entities/bi-1910.json